Fig 1.
Schematic diagram of data extraction, processing, and analysis.
DEMO: demographic records, DRUG: drug information, REAC: adverse event reports.
Table 1.
Basic characteristics of adverse event reports related to Cholestyramine, Colestipol, and Colesevelam from FAERS.
Fig 2.
Temporal trends in adverse event reporting for bile acid sequestrants.
Fig 3.
Distribution of adverse events by MedDRA System Organ Class for three bile acid sequestrants.
Fig 4.
Adverse event signal distribution of cholestyramine at Preferred Term level.
Top 30 PTs ranked by report frequency. SOC, System Organ Class; a, number of reports containing both the target drug and the target adverse drug reaction; ROR, Reporting Odds Ratio.
Fig 5.
Adverse event signal distribution of colestipol at Preferred Term level.
Top 30 PTs ranked by report frequency. SOC, System Organ Class; a, number of reports containing both the target drug and the target adverse drug reaction; ROR, Reporting Odds Ratio.
Fig 6.
Adverse event signal distribution of colesevelam at Preferred Term level.
Top 30 PTs ranked by report frequency. SOC, System Organ Class; a, number of reports containing both the target drug and the target adverse drug reaction; ROR, Reporting Odds Ratio.
Fig 7.
Consensus adverse event signals of bile acid sequestrants identified by intersection analysis of four disproportionality methods.
A: cholestyramine; B: colestipol; C: colesevelam. ROR, Reporting Odds Ratio; PRR, Proportional Reporting Ratio; BCPNN, Bayesian Confidence Propagation Neural Network; MGPS, Multi-item Gamma Poisson Shrinker.
Fig 8.
Time-to-onset analysis of adverse events associated with three bile acid sequestrants.